Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V et al (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37(5):423–438. https://doi.org/10.1200/JCO.18.01160
Article CAS PubMed Google Scholar
Bekes I, Huober J (2023) Extended adjuvant endocrine therapy in early breast cancer patients—review and perspectives. Cancers 15(16):4190. https://doi.org/10.3390/cancers15164190
Article CAS PubMed PubMed Central Google Scholar
Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE (1998) Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J Clin Oncol 16(2):501–514. https://doi.org/10.1200/jco.1998.16.2.501
Article CAS PubMed Google Scholar
Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107(2):167–180. https://doi.org/10.1007/s10549-007-9548-1
Article CAS PubMed Google Scholar
Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M et al (2016) treatment adherence and its impact on disease-free survival in the breast international group 1–98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol 34(21):2452–2459. https://doi.org/10.1200/jco.2015.63.8619
Article CAS PubMed PubMed Central Google Scholar
Pearson T (2011) Atrophic Vaginitis. J Nurse Practitioners 7(6):502–512. https://doi.org/10.1016/j.nurpra.2010.08.016
Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M (2008) Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 13(3):222–231. https://doi.org/10.1634/theoncologist.2007-0234
Santen RJ, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L, Klein KO (2002) Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 9(3):179–187. https://doi.org/10.1097/00042192-200205000-00006
Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, Ravarino N, Ponzone R, Sismondi P (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 26(6):404–412. https://doi.org/10.3109/09513591003632258
Article CAS PubMed Google Scholar
Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M (2008) Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 111(1):67–76. https://doi.org/10.1097/01.AOG.0000296714.12226.0f
Article CAS PubMed Google Scholar
Notelovitz M, Funk S, Nanavati N, Mazzeo M (2002) Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 99(4):556–562. https://doi.org/10.1016/s0029-7844(01)01385-0
Article CAS PubMed Google Scholar
Agrawal P, Singh SM, Able C, Dumas K, Kohn J, Kohn TP, Clifton M (2023) Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer. Obstet Gynecol 142(3):660–668. https://doi.org/10.1097/aog.0000000000005294
Cold S, Cold F, Jensen M-B, Cronin-Fenton D, Christiansen P, Ejlertsen B (2022) Systemic or vaginal hormone therapy after early breast cancer: a danish observational cohort study. JNCI: J Natl Cancer Inst 114(10):1347–1354. https://doi.org/10.1093/jnci/djac112
Article CAS PubMed PubMed Central Google Scholar
Le Ray I, Dell’Aniello S, Bonnetain F, Azoulay L, Suissa S (2012) Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 135(2):603–609. https://doi.org/10.1007/s10549-012-2198-y
Article CAS PubMed Google Scholar
McVicker L, Labeit AM, Coupland CAC, Hicks B, Hughes C, McMenamin Ú, McIntosh SA, Murchie P, Cardwell CR (2024) Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol 10(1):103–108. https://doi.org/10.1001/jamaoncol.2023.4508
Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17(4):584–587. https://doi.org/10.1093/annonc/mdj127
Article CAS PubMed Google Scholar
Sulaica E, Han T, Wang W, Bhat R, Trivedi MV, Niravath P (2016) Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat 157(2):203–210. https://doi.org/10.1007/s10549-016-3827-7
Article CAS PubMed Google Scholar
Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes DF, Decker DA (2012) Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 8(3):144–148. https://doi.org/10.1200/jop.2011.000352
Article PubMed PubMed Central Google Scholar
Pearson A, Chen J, Dhillon HM, Kiely BE (2024) Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review. Breast Cancer Res Treat 206(2):215–226. https://doi.org/10.1007/s10549-024-07364-0
Article PubMed PubMed Central Google Scholar
Savolainen-Peltonen H, Hautamäki H, Tuomikoski P, Ylikorkala O, Mikkola TS (2014) Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy. Menopause 21(7):732–739. https://doi.org/10.1097/gme.0000000000000120
Faltinová M, Vehmanen L, Lyytinen H, Haanpää M, Hämäläinen E, Tiitinen A, Blomqvist C, Mattson J (2021) Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. Breast Cancer Res Treat 187(3):769–775. https://doi.org/10.1007/s10549-021-06168-w
Article CAS PubMed Google Scholar
Faltinová M, Vehmanen L, Lyytinen H, Haanpää M, Hämäläinen E, Tiitinen A, Blomqvist C, Mattson J (2023) Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurement. Breast Cancer Res Treat 201(3):425–435. https://doi.org/10.1007/s10549-023-07054-3
Article CAS PubMed PubMed Central Google Scholar
Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431–2442. https://doi.org/10.1200/jco.2005.05.369424
Article CAS PubMed Google Scholar
Santen RJ, Mirkin S, Bernick B, Constantine GD (2020) Systemic estradiol levels with low-dose vaginal estrogens. Menopause 27(3):361–370. https://doi.org/10.1097/gme.0000000000001463
Hetemäki N, Robciuc A, Vihma V, Haanpää M, Hämäläinen E, Tikkanen MJ, Mikkola TS, Savolainen-Peltonen H (2024) Adipose tissue sex steroids in postmenopausal women with and without menopausal hormone therapy. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgae458
Hetemäki N, Savolainen-Peltonen H, Tikkanen MJ, Wang F, Paatela H, Hämäläinen E, Turpeinen U, Haanpää M, Vihma V, Mikkola TS (2017) Estrogen metabolism in abdominal subcutaneous and visceral adipose tissue in postmenopausal women. J Clin Endocrinol Metab 102(12):4588–4595. https://doi.org/10.1210/clinem/dgae45810.1210/jc.2017-01474
Folkerd EJ, Lønning PE, Dowsett M (2014) Interpreting plasma estrogen levels in breast cancer: caution needed. J Clin Oncol 32(14):1396–1400. https://doi.org/10.1200/jco.2013.53.9411
留言 (0)